These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 25614274)

  • 1. Denosumab for the treatment of osteoporosis.
    Zaheer S; LeBoff M; Lewiecki EM
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):461-70. PubMed ID: 25614274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R; Khan A; Ngui D; Shapiro M
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M; Levancini M
    Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
    Capozzi A; Lello S; Pontecorvi A
    Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab in osteoporosis.
    Diab DL; Watts NB
    Expert Opin Drug Saf; 2014 Feb; 13(2):247-53. PubMed ID: 24289327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
    Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
    Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Denosumab - a new option in the treatment of osteoporosis].
    Franek E
    Endokrynol Pol; 2011; 62 Suppl 2():37-41. PubMed ID: 22125021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab: a novel antiresorptive drug for osteoporosis.
    Suresh E; Abrahamsen B
    Cleve Clin J Med; 2015 Feb; 82(2):105-14. PubMed ID: 25897599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.
    Kendler DL; Cosman F; Stad RK; Ferrari S
    Adv Ther; 2022 Jan; 39(1):58-74. PubMed ID: 34762286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New anti-resorptives and antibody mediated anti-resorptive therapy.
    Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
    Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.
    Harris KB; Nealy KL; Jackson DJ; Thornton PL
    J Pharm Pract; 2012 Jun; 25(3):310-8. PubMed ID: 22550161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of denosumab on cortical and trabecular microarchitecture: evidences from clinical studies.
    Iolascon G; Resmini G; Tarantino U
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S19-22. PubMed ID: 24046050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U; Halse JI; Geisler J; Eriksen EF
    Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on denosumab in postmenopausal osteoporosis.
    Moen MD; Keam SJ
    BioDrugs; 2011 Aug; 25(4):261-4. PubMed ID: 21815702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.
    Tarantino U; Celi M; Feola M; Liuni FM; Resmini G; Iolascon G
    Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S65-9. PubMed ID: 24046047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis.
    McClung MR; Boonen S; Törring O; Roux C; Rizzoli R; Bone HG; Benhamou CL; Lems WF; Minisola S; Halse J; Hoeck HC; Eastell R; Wang A; Siddhanti S; Cummings SR
    J Bone Miner Res; 2012 Jan; 27(1):211-8. PubMed ID: 21976367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.